Pharma Five is a registered firm based in India. We specialize in Named Patient Imports, Imported cancer drugs, Imported medicines in india.
Contact Us Pharma Five Door No. 74, Old No. 26, Fagun Mansion, 3rd Floor, Ethiraj Salai, Egmore, Chennai - 600008 +916374297988 info@pharmafive.org
Medicine name : Jemperli
Generic name : Dostarlimab-gxly
Manufactured By : GSK
Indications : Treatment of adults with Stage II or III locally advanced microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) rectal cancer.
Medicine Description : An immunotherapy for adults with Stage II or III locally advanced MSI-H or dMMR rectal cancer. Jemperli (Dostarlimab-gxly) blocks the PD-1 protein, helping the immune system recognise and attack cancer cells.
Jemperli (Dostarlimab-gxly) is an immunotherapy medicine used to treat certain cancers. It is indicated for adults with Stage II or Stage III locally advanced MSI-H or dMMR rectal cancer under the FDA accelerated approval pathway.
Jemperli blocks the PD-1 pathway, preventing cancer cells from suppressing immune activity. This helps the body's T cells recognise and attack cancer cells.
Jemperli is prescribed for eligible adults with certain cancers, including Stage II or Stage III locally advanced MSI-H or dMMR rectal cancer. A specialist confirms the diagnosis and biomarker status before recommending treatment.
Jemperli is administered through an intravenous infusion by a qualified healthcare professional, usually over approximately 30 minutes. The dose and treatment schedule depend on the cancer type and prescribed regimen.
Common side effects may include fatigue, skin rash, diarrhoea, itching, nausea, constipation, headache, joint pain, fever and decreased appetite.
Yes. Jemperli can cause serious immune-related reactions affecting the lungs, liver, kidneys, intestines, thyroid and other organs. Severe skin reactions and infusion-related reactions may also occur. Report unusual or worsening symptoms promptly.
Treatment duration depends on the cancer type, treatment response and side effects. For the Stage II or III locally advanced MSI-H or dMMR rectal cancer regimen, the prescribed schedule may include 500 mg every three weeks for nine cycles. Your oncologist determines the appropriate duration.
Consult your doctor before consuming alcohol during treatment. Discuss alcohol use with your healthcare team, particularly if you experience fatigue, nausea or other treatment-related symptoms.
Jemperli may cause harm to an unborn baby. Women who can become pregnant should use effective contraception during treatment and for 4 months after the last dose.
Inform your doctor about all prescription medicines, over-the-counter products, vitamins and supplements you use. Your healthcare team should also know about any other cancer treatments or immune-modulating medicines.
If you miss a scheduled infusion, contact your healthcare provider as soon as possible to arrange another appointment. Do not attempt to compensate for the missed dose yourself.
Jemperli is administered directly into a vein, so food does not affect its administration. Follow your doctor's dietary recommendations during treatment.
Attend all scheduled appointments and blood tests. Inform your doctor about existing medical conditions and report persistent diarrhoea, breathing difficulties, severe rash, yellowing of the skin or other unusual symptoms promptly.
Store unopened Jemperli vials in a refrigerator at 2°C to 8°C (36°F to 46°F), in the original carton to protect them from light. Do not freeze or shake the vials.
Pharma Five provides medicine consultancy and import facilitation for patients seeking Jemperli (Dostarlimab-gxly). Assistance with personal-use medicine imports is subject to applicable regulations, prescriptions and supporting documentation. Pharma Five assists in its procurement.